Trial Profile

An Open-Label, Dose Escalation, Phase 1, First-in-Human Study of TAK-164, an Antibody-Drug Conjugate, in Patients With Advanced Gastrointestinal Cancers Expressing Guanylyl Cyclase C

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 20 Apr 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs TAK-164 (Primary)
Indications Carcinoma; Colon cancer; Colorectal cancer; Gastric cancer; Gastrointestinal cancer; Oesophageal cancer; Pancreatic cancer
Focus Adverse reactions; First in man
Sponsors Takeda Oncology

Most Recent Events

01 Apr 2023 Results assessing the safety and tolerability of TAK-164 in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C, published in the Cancer Chemotherapy and Pharmacology.
08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
24 Feb 2021 Status changed from completed to discontinued.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com